Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cost of Revenue (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of Cost of Revenue data on record, last reported at $11.7 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 69.27% year-over-year to $11.7 million; the TTM value through Dec 2025 reached $36.7 million, up 91.84%, while the annual FY2025 figure was $36.7 million, 91.84% up from the prior year.
  • Cost of Revenue reached $11.7 million in Q4 2025 per ARQT's latest filing, up from $8.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $11.7 million in Q4 2025 and bottomed at $269000.0 in Q3 2022.
  • Average Cost of Revenue over 4 years is $4.4 million, with a median of $3.4 million recorded in 2024.
  • Peak YoY movement for Cost of Revenue: surged 365.57% in 2024, then soared 57.82% in 2025.
  • A 4-year view of Cost of Revenue shows it stood at $485000.0 in 2022, then surged by 363.09% to $2.2 million in 2023, then surged by 207.44% to $6.9 million in 2024, then surged by 69.27% to $11.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $11.7 million in Q4 2025, $8.7 million in Q3 2025, and $7.5 million in Q2 2025.